Ethyl chlorophenoxyisobutyrate (CPIB) effects in juvenile-onset diabetes mellitus.
D000293:Adolescent; D000328:Adult; D000738:Androsterone / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D002087:Butyrates / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D004562:Electrocardiography; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D007677:Kidney Function Tests; D008055:Lipids; D008111:Liver Function Tests; D008297:Male; D010919:Placebos; D013960:Thyroid Function Tests
D000924:Anticholesteremic Agents; D002087:Butyrates; D008055:Lipids; D010919:Placebos; D000738:Androsterone